vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and WORKIVA INC (WK). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($268.1M vs $247.3M, roughly 1.1× WORKIVA INC). WORKIVA INC runs the higher net margin — 7.7% vs 1.4%, a 6.3% gap on every dollar of revenue. On growth, WORKIVA INC posted the faster year-over-year revenue change (19.9% vs 9.7%). Over the past eight quarters, WORKIVA INC's revenue compounded faster (18.0% CAGR vs 5.3%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Workiva, Inc. is a global software-as-a-service (SaaS) company. It provides a cloud-based connected and reporting compliance platform that enables the use of connected data and automation of reporting across finance, accounting, risk, and compliance.
ACAD vs WK — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $268.1M | $247.3M |
| Net Profit | $3.6M | $19.0M |
| Gross Margin | — | 80.4% |
| Operating Margin | -1.7% | 25.8% |
| Net Margin | 1.4% | 7.7% |
| Revenue YoY | 9.7% | 19.9% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.02 | $0.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $268.1M | $247.3M | ||
| Q4 25 | $284.0M | $238.9M | ||
| Q3 25 | $278.6M | $224.2M | ||
| Q2 25 | $264.6M | $215.2M | ||
| Q1 25 | $244.3M | $206.3M | ||
| Q4 24 | $259.6M | $199.9M | ||
| Q3 24 | $250.4M | $185.6M | ||
| Q2 24 | $242.0M | $177.5M |
| Q1 26 | $3.6M | $19.0M | ||
| Q4 25 | $273.6M | $11.8M | ||
| Q3 25 | $71.8M | $2.8M | ||
| Q2 25 | $26.7M | $-19.4M | ||
| Q1 25 | $19.0M | $-21.4M | ||
| Q4 24 | $143.7M | $-8.8M | ||
| Q3 24 | $32.8M | $-17.0M | ||
| Q2 24 | $33.4M | $-17.5M |
| Q1 26 | — | 80.4% | ||
| Q4 25 | 90.8% | 80.7% | ||
| Q3 25 | 92.2% | 79.3% | ||
| Q2 25 | 92.2% | 77.0% | ||
| Q1 25 | 91.7% | 76.6% | ||
| Q4 24 | 91.6% | 77.1% | ||
| Q3 24 | 92.5% | 76.5% | ||
| Q2 24 | 92.5% | 76.8% |
| Q1 26 | -1.7% | 25.8% | ||
| Q4 25 | 6.1% | 3.3% | ||
| Q3 25 | 12.8% | -1.5% | ||
| Q2 25 | 12.2% | -10.3% | ||
| Q1 25 | 7.9% | -12.0% | ||
| Q4 24 | 59.1% | -6.7% | ||
| Q3 24 | 12.6% | -11.7% | ||
| Q2 24 | 12.6% | -13.0% |
| Q1 26 | 1.4% | 7.7% | ||
| Q4 25 | 96.3% | 4.9% | ||
| Q3 25 | 25.8% | 1.2% | ||
| Q2 25 | 10.1% | -9.0% | ||
| Q1 25 | 7.8% | -10.4% | ||
| Q4 24 | 55.4% | -4.4% | ||
| Q3 24 | 13.1% | -9.2% | ||
| Q2 24 | 13.8% | -9.9% |
| Q1 26 | $0.02 | $0.33 | ||
| Q4 25 | $1.61 | $0.21 | ||
| Q3 25 | $0.42 | $0.05 | ||
| Q2 25 | $0.16 | $-0.35 | ||
| Q1 25 | $0.11 | $-0.38 | ||
| Q4 24 | $0.86 | $-0.15 | ||
| Q3 24 | $0.20 | $-0.31 | ||
| Q2 24 | $0.20 | $-0.32 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $334.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | — |
| Total Assets | $1.6B | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $334.3M | ||
| Q4 25 | $177.7M | $338.8M | ||
| Q3 25 | $258.0M | $315.9M | ||
| Q2 25 | $253.6M | $284.3M | ||
| Q1 25 | $217.7M | $242.0M | ||
| Q4 24 | $319.6M | $301.8M | ||
| Q3 24 | $155.1M | $248.2M | ||
| Q2 24 | $177.1M | $267.9M |
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | $-5.4M | ||
| Q3 25 | $917.3M | $-36.9M | ||
| Q2 25 | $822.4M | $-66.5M | ||
| Q1 25 | $765.2M | $-75.7M | ||
| Q4 24 | $732.8M | $-41.7M | ||
| Q3 24 | $577.2M | $-50.8M | ||
| Q2 24 | $516.7M | $-77.7M |
| Q1 26 | $1.6B | $1.4B | ||
| Q4 25 | $1.6B | $1.5B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $1.1B | $1.3B | ||
| Q4 24 | $1.2B | $1.4B | ||
| Q3 24 | $976.9M | $1.3B | ||
| Q2 24 | $914.1M | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | — |
| Free Cash FlowOCF − Capex | — | $25.7M |
| FCF MarginFCF / Revenue | — | 10.4% |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $171.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-48.7M | $51.0M | ||
| Q3 25 | $74.3M | $46.2M | ||
| Q2 25 | $64.0M | $50.3M | ||
| Q1 25 | $20.3M | $-7.4M | ||
| Q4 24 | $40.4M | $44.0M | ||
| Q3 24 | $63.2M | $18.9M | ||
| Q2 24 | $25.0M | $-14.0K |
| Q1 26 | — | $25.7M | ||
| Q4 25 | — | $50.7M | ||
| Q3 25 | $73.9M | $46.1M | ||
| Q2 25 | — | $49.3M | ||
| Q1 25 | — | $-8.1M | ||
| Q4 24 | — | $43.2M | ||
| Q3 24 | $63.2M | $18.7M | ||
| Q2 24 | — | $-122.0K |
| Q1 26 | — | 10.4% | ||
| Q4 25 | — | 21.2% | ||
| Q3 25 | 26.5% | 20.5% | ||
| Q2 25 | — | 22.9% | ||
| Q1 25 | — | -3.9% | ||
| Q4 24 | — | 21.6% | ||
| Q3 24 | 25.2% | 10.1% | ||
| Q2 24 | — | -0.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | 0.1% | 0.0% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 0.4% | ||
| Q3 24 | 0.0% | 0.1% | ||
| Q2 24 | — | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | -0.18× | 4.31× | ||
| Q3 25 | 1.03× | 16.57× | ||
| Q2 25 | 2.40× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
Segment breakdown not available.
WK
| Subscription and support | $225.4M | 91% |
| Other | $22.0M | 9% |
